UBS has issued a research report highlighting positive clinical data for Hengrui Pharma (HKG: 01276)'s weight-loss drug candidate HRS-7535. The Phase III clinical trial for the drug has successfully met its primary endpoint, and the company is expected to submit a New Drug Application (NDA) in China this year.
The bank's analysis indicates the clinical results for HRS-7535 are favorable. At the 44-week mark, the group receiving a once-daily 180mg dose recorded a weight reduction of 9.8%, with the weight-loss effect showing no signs of plateauing. The drug was also reported to have a good tolerability profile.
UBS forecasts that Hengrui's portfolio of GLP-1 products could achieve sales of up to 5.9 billion yuan in the Chinese market by 2035. The report also notes that the company has successfully met primary endpoints in two separate domestic Phase III clinical trials targeting type 2 diabetes.
Based on this outlook and the drug's promising data, UBS has reaffirmed its 'Buy' rating on Hengrui Pharma. The bank has set a target price of HK$97.4 for the company's H-shares.
- Like
- Comment
- Favorite
UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation
Stock News07-09 17:20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet